Business
Change of Adviser
Change of Adviser.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 2470J Sareum Holdings PLC 16 August 2019 \n\n(AIM:SAR) 16 August 2019\nSareum Holdings PLC\n(\"Sareum\" or the \"Company\")\nAppointment of Nominated Adviser\n \n \nSareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, is pleased to announce the appointment of Strand Hanson Limited as Nominated & Financial Adviser to the Company with immediate effect. \n \nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.\n \nFor further information, contact:\n \n\n\n\nSareum Holdings PLC\n\n\n\n\n\n\n\nTim Mitchell\n\n\n+44 (0) 12 2349 7700 \n\n\n\n\n\n\n\n\n\n\n\n\nStrand Hanson Limited (Nominated & Financial Adviser) \n\n\n+44 (0) 20 7409 3494\n\n\n\n\nRichard Tulloch\n\n\n\n\n\n\n\nJames Dance\n\n\n\n\n\n\n\nEric Allan\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nHybridan LLP (Broker)\n\n\n+44 (0) 20 3764 2341\n\n\n\n\nClaire Noyce\n\n\n\n\n\n\n\nJohn Beresford-Peirse\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCitigate Dewe Rogerson (Media enquiries)\n\n\n+44 (0) 20 7638 9571\n\n\n\n\nShabnam Bashir\n\n\n\n\n\n\n\nMark Swallow\n\n\n\n\n\n\n\nDavid Dible\n\n\n\n\n\n\n \nNotes to editor:\nSareum is a specialist drug development company delivering targeted small molecule therapeutics, to improve the treatment of cancer and autoimmune disease. The Company generates value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stag...